| Date | Title | Description | |
|---|---|---|---|
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 28 Jul 2023 | On business and financial situation | ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® | Download |
| 05 Jul 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2023 | Download |
| 26 Jun 2023 | Other relevant information | The Company informs about the dividends payment | Download |
| 14 Jun 2023 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting. | Download |
| 31 May 2023 | Other relevant information | ROVI informs about the news items that have appeared in several media today regarding ROVI’s receipt of government grants | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2019 | Information on P&L | ROVI releases the first nine months 2019 results presentation | Download |
| 03 Oct 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2019 | Download |
| 05 Sep 2019 | Others on business performance and financial information | The Company informs about the construction of a second heparin plant in Granada | Download |
| 30 Jul 2019 | Information on P&L | ROVI releases the first half 2019 results presentation | Download |
| 30 Jul 2019 | Information on P&L | ROVI releases the press release related to the first half 2019 financial results | Download |